Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics (NASDAQ: BCTX) has announced two clinical data poster presentations at the upcoming ESMO Congress 2025 in Berlin, Germany. The presentations will focus on the company's Phase III pivotal trial of Bria-IMT combined with CPI for advanced metastatic breast cancer treatment.

The two posters (#8212 and #3928) will present data on the BRIA-ABC trial, examining both the pivotal trial results and the feasibility and biomarker validation aspects of this international randomized Phase 3 study. The abstracts will be published on the ESMO website on October 13th, 2025, with the congress taking place from October 17-21, 2025.

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company focused on immunotherapy for cancer care, has successfully closed a $15 million public offering. The offering consisted of 12 million units priced at $1.25 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.

The warrants are exercisable at $1.50 per share for a five-year period, while pre-funded warrants have an exercise price of $0.001. ThinkEquity served as the sole placement agent. The company plans to utilize the proceeds for working capital, general corporate purposes, and advancing its business objectives.

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced the pricing of a $15 million public offering. The offering consists of 12 million units priced at $1.25 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.

The warrants are immediately exercisable at $1.50 per share with a five-year expiration term. ThinkEquity is serving as the sole placement agent, and the offering is expected to close on July 16, 2025. The company plans to use the proceeds for working capital, general corporate purposes, and advancing business objectives.

BriaCell Therapeutics (NASDAQ: BCTX) has announced the addition of Mayo Clinic as a clinical site for its pivotal Phase 3 study in metastatic breast cancer. The study now encompasses 69 active clinical sites across 15 states.

The Phase 3 trial is evaluating Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer. The study's primary endpoint will analyze interim data after 144 patient events (deaths), comparing overall survival between treatment groups. The company recently reported positive Phase 2 survival data at ASCO 2025, and the Bria-IMT combination regimen has received FDA Fast Track designation.

BriaCell Therapeutics (NASDAQ: BCTX) has reported promising Phase 2 survival data for its Bria-IMT™ immunotherapy in combination with checkpoint inhibitors for metastatic breast cancer treatment. The study showed significant survival advantages over Trodelvy® and control groups:

In triple negative breast cancer (TNBC), Bria-IMT achieved median overall survival of 13.9 months, surpassing Trodelvy (11.8 months) and doubling control group (6.9 months). For hormone receptor positive (HR+) patients, Bria-IMT reached 17.3 months median survival versus Trodelvy's 14.4 months and control's 11.2 months.

The Phase 2 study included 54 heavily pre-treated patients who had received a median of 6 prior therapies. Notably, no Bria-IMT related treatment discontinuations were reported, and the company is currently conducting a pivotal Phase 3 study.

BriaCell Therapeutics (NASDAQ: BCTX) has reported significant progress in its Phase 2 study of Bria-IMT™ immunotherapy for advanced metastatic breast cancer. A patient who had previously failed 8 prior treatment regimens has shown remarkable results after 18+ months of treatment, including complete resolution of temporal lobe brain metastasis and continued reduction of orbital tumor that had caused eye bulging.

The patient has completed 29 treatment cycles over 21 months, with serial imaging at 8, 11, and 20 months confirming no detectable disease in the right temporal lobe and continued response in the orbital lesion. Tumor markers have remained significantly reduced from baseline, supporting the sustained radiologic response.

BriaCell Therapeutics (NASDAQ: BCTX) reported sustained complete resolution of lung metastasis in the first patient treated with Bria-OTS, their personalized off-the-shelf immunotherapy for metastatic breast cancer. The 78-year-old patient with hormone receptor-positive, HER2-negative metastatic breast cancer showed 100% resolution of lung metastasis, maintained at 2, 4, and 6 months after treatment.

The patient, who had multiple prior treatment failures, has received 12 cycles of Bria-OTS monotherapy with no treatment-limiting toxicities. This milestone was achieved at the lowest dose level, demonstrating strong single-agent activity in a challenging patient population.

BriaCell Therapeutics (NASDAQ: BCTX) has reported impressive survival data from its Phase 2 clinical study of Bria-IMT in metastatic breast cancer patients. The study showed that 52% of the most recent 25-patient cohort survived beyond one year, surpassing current standard of care expectations. Notably, 11 patients remain alive, with two remarkable cases reaching 38.3 and 30.3 months of survival.

The study included heavily pre-treated patients who had previously failed multiple therapies, including checkpoint inhibitors and antibody-drug conjugates. The median number of prior treatments was 6, and importantly, no treatment discontinuations related to Bria-IMT have been reported, suggesting a well-tolerated profile.

BriaCell Therapeutics (NASDAQ: BCTX) has expanded its pivotal Phase 3 clinical trial for advanced metastatic breast cancer treatment by adding two major cancer centers: Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, contributing 30 additional satellite locations. The study now encompasses 58 active clinical sites across 15 states.

The trial evaluates BriaCell's lead candidate Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice. Patient enrollment is expected to complete by late 2025 or early 2026, with potential top-line data release in H1-2026. The study's primary endpoint will analyze overall survival after 144 patient events, with positive results potentially leading to full approval and marketing authorization.